HIV-1
Clinical trials for HIV-1 explained in plain language.
Never miss a new study
Get alerted when new HIV-1 trials appear
Sign up with your email to follow new studies for HIV-1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a cancer drug flush out hidden HIV?
Disease control Recruiting nowThis study tests whether adding venetoclax, a drug that promotes cell death, to standard HIV treatment can kill cells that harbor dormant HIV. The goal is to shrink the hidden virus reservoir, which is the main barrier to a cure. About 38 adults newly starting HIV therapy will re…
Matched conditions: HIV-1
Phase: PHASE1 • Sponsor: Thomas Aagaard Rasmussen • Aim: Disease control
Last updated May 16, 2026 22:29 UTC
-
Could a Two-Drug HIV pill be enough for transgender women?
Disease control Recruiting nowThis study tests if switching to a two-drug combination (dolutegravir and lamivudine) can safely keep HIV under control in transgender women who are already on a stable three-drug regimen. About 50 participants will take the new pills for 48 weeks. The goal is to see if the simpl…
Matched conditions: HIV-1
Phase: PHASE4 • Sponsor: UBATEC • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
Engineered immune cells aim to keep HIV in check
Disease control Recruiting nowThis study tests a new treatment for people living with HIV. It uses specially designed immune cells (CMV-HIV CAR T cells) to target and control the virus. The goal is to see if this approach is safe and possible, while participants continue their regular HIV medications. About 1…
Matched conditions: HIV-1
Phase: EARLY_PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 04, 2026 16:31 UTC
-
New study tests antibodies to shield HIV-Exposed newborns
Prevention Recruiting nowThis study tests whether giving special antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV is safe and how long they stay in the body. About 48 infants will receive one or two doses soon after birth. The goal is to see if these antibodies can help prevent HIV i…
Matched conditions: HIV-1
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated May 08, 2026 12:04 UTC